Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness
Incannex Healthcare supports the new White House Executive Order aimed at accelerating access to psychedelic treatments for serious mental illness, stating that its PSX-001 program aligns with these federal goals. The company highlighted Phase 2 data for PSX-001, which demonstrated a statistically significant 12.8-point reduction in HAM-A anxiety scores versus placebo and a 44% clinical response rate. Management noted that with over $70 million in cash, no debt, and an active U.S.
Key figures
- Drug Name
- PSX-001
- Phase Of Trial
- Phase 2
- P value
- p<0.0001
- Patient count
- 73
- Cash on hand usd
- $70 million
- Response rate drug
- 44%
- Remission rate drug
- 27%
- Ham a reduction drug
- 12.8
- Ham a reduction placebo
- 3.6
- Sustained remission weeks
- 11
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.